118
IRUS TotalDownloads
Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
File | Description | Size | Format | |
---|---|---|---|---|
![]() | Published version | 3.02 MB | Adobe PDF | View/Open |
Title: | Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England |
Authors: | Knock, ES Whittles, LK Lees, JA Perez-Guzman, PN Verity, R FitzJohn, RG Gaythorpe, KAM Imai, N Hinsley, W Okell, LC Rosello, A Kantas, N Walters, CE Bhatia, S Watson, OJ Whittaker, C Cattarino, L Boonyasiri, A Djaafara, BA Fraser, K Fu, H Wang, H Xi, X Donnelly, CA Jauneikaite, E Laydon, DJ White, PJ Ghani, AC Ferguson, NM Cori, A Baguelin, M |
Item Type: | Journal Article |
Abstract: | We fitted a model of SARS-CoV-2 transmission in care homes and the community to regional surveillance data for England. Compared with other approaches, our model provides a synthesis of multiple surveillance data streams into a single coherent modelling framework allowing transmission and severity to be disentangled from features of the surveillance system. Of the control measures implemented, only national lockdown brought the reproduction number (Rteff ) below 1 consistently; if introduced one week earlier it could have reduced deaths in the first wave from an estimated 48,600 to 25,600 (95% credible interval [95%CrI]: 15,900-38,400). The infection fatality ratio decreased from 1.00% (95%CrI: 0.85%-1.21%) to 0.79% (95%CrI: 0.63%-0.99%), suggesting improved clinical care. The infection fatality ratio was higher in the elderly residing in care homes (23.3%, 95%CrI: 14.7%-35.2%) than those residing in the community (7.9%, 95%CrI: 5.9%-10.3%). On 2nd December 2020 England was still far from herd immunity, with regional cumulative infection incidence between 7.6% (95%CrI: 5.4%-10.2%) and 22.3% (95%CrI: 19.4%-25.4%) of the population. Therefore, any vaccination campaign will need to achieve high coverage and a high degree of protection in vaccinated individuals to allow non-pharmaceutical interventions to be lifted without a resurgence of transmission. |
Issue Date: | 14-Jul-2021 |
Date of Acceptance: | 16-Jun-2021 |
URI: | http://hdl.handle.net/10044/1/90018 |
DOI: | 10.1126/scitranslmed.abg4262 |
ISSN: | 1946-6234 |
Publisher: | American Association for the Advancement of Science |
Start Page: | 1 |
End Page: | 12 |
Journal / Book Title: | Science Translational Medicine |
Volume: | 13 |
Issue: | 602 |
Copyright Statement: | © 2021, American Association for the Advancement of Science https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Sponsor/Funder: | United States Agency for International Development (USAID) Medical Research Council (MRC) National Institute for Health Research |
Funder's Grant Number: | AID-OAA-F-16-00115 MR/R015600/1 NIHR200908 |
Keywords: | Aged COVID-19 Communicable Disease Control England Epidemics Humans SARS-CoV-2 Humans Communicable Disease Control Aged England Epidemics COVID-19 SARS-CoV-2 06 Biological Sciences 11 Medical and Health Sciences |
Publication Status: | Published |
Conference Place: | United States |
Online Publication Date: | 2021-07-14 |
Appears in Collections: | Department of Infectious Diseases Statistics Faculty of Medicine Imperial College London COVID-19 School of Public Health Faculty of Natural Sciences Mathematics |
This item is licensed under a Creative Commons License